keyword
https://read.qxmd.com/read/37898423/comparative-efficacy-and-side-effect-profiles-of-interventions-for-pediatric-saliva-control-a-cohort-study
#21
JOURNAL ARTICLE
Apostolos Papandreou, Aoife Mahony, Anne Breaks, Michael Absoud, Charlie Fairhurst
OBJECTIVE: To compare efficacy and side effect profile data on conservative, behavioral, pharmacological, and surgical treatments used for pediatric saliva control. STUDY DESIGN: A cohort study of children (n = 483) referred to a specialty Saliva Control service between May 2014 and November 2019 was performed, using quantitative data from pretreatment and post-treatment questionnaires (the Drooling Impact Scale [DIS], Drooling Rating Scale [DRS]) and recording of side effects...
February 2024: Journal of Pediatrics
https://read.qxmd.com/read/37854895/compliance-with-national-and-international-guidelines-in-the-treatment-of-nonmotor-symptoms-in-late-stage-parkinson-s-disease
#22
JOURNAL ARTICLE
Kristina Rosqvist, Per Odin
BACKGROUND: National as well as international Parkinson's disease (PD) treatment guidelines are available to guide clinicians. Previous research has shown that nonmotor symptoms (NMS) are pronounced in late-stage PD and has suggested that current treatment is insufficient and could be improved. OBJECTIVES: The aim of this study was to investigate to which degree the national and international treatment guidelines are followed in the treatment of NMS in late-stage PD...
2023: Parkinson's Disease
https://read.qxmd.com/read/37849615/ultrasound-guidance-superiority-in-pediatric-sialorrhea-treatment-with-intraglandular-botulinum-toxin-application-a-four-year-retrospective-study
#23
JOURNAL ARTICLE
Mafalda Pires, Joana Saldanha, Sandra Claro
Introduction The management of sialorrhea in children with multiple disabilities is extremely important not only for aesthetic/psychosocial reasons but also for functional and clinical ones. There are several recommended management methods with strong evidence of the effectiveness of intraglandular application of botulinum toxin A. Materials and methods In this four-year retrospective report, we compare two populations who received intraglandular type A botulinum toxin injections in the pediatric unit of the Physical Medicine and Rehabilitation (PM&R) Department at a central hospital...
September 2023: Curēus
https://read.qxmd.com/read/37828600/the-effectiveness-and-safety-of-botulinum-toxin-injections-for-the-treatment-of-sialorrhea-with-parkinson-s-disease-a-systematic-review-and-meta-analysis
#24
JOURNAL ARTICLE
Chun-Lan Yang, Jia-Peng Huang, Ying-Chao Tan, Ting-Ting Wang, Han Zhang, Yun Qu
BACKGROUND: Botulinum toxin (BoNT) injection is an important adjunctive method to treat sialorrhea. The purpose of this systematic review was to analyze the effect and safety of BoNT injections in the intervention of sialorrhea with Parkinson's disease (PD). METHODS: We searched PubMed, Web Of Science (WOS), Scopus, Cochrane CENTRAL, and Embase from inception until April 2022. Randomized controlled trials or randomized crossover trials comparing BoNT with placebo in sialorrhea with PD were eligible...
October 12, 2023: BMC Pharmacology & Toxicology
https://read.qxmd.com/read/37821573/pharmacological-interventions-for-antipsychotic-related-sialorrhea-a-systematic-review-and-network-meta-analysis-of-randomized-trials
#25
Michele Fornaro, Claudio Caiazza, Niccolò Solini, Michele De Prisco, Martina Billeci, Martina Vannini, Risa Shorr, Stefano Caiolo, Marialaura Lussignoli, Dan Siskind, Giorgio Pigato, Annarita Barone, Fabio Sambataro, Andrea de Bartolomeis, Christoph U Correll, Marco Solmi
Antipsychotic-induced sialorrhea carries a significant burden, but evidence-based treatment guidance is incomplete, warranting network meta-analysis (NMA) of pharmacological interventions for antipsychotic-related sialorrhea. PubMed Central/PsycInfo/Cochrane Central database/Clinicaltrials.gov/WHO-ICTRP and the Chinese Electronic Journal Database (Qikan.cqvip.com) were searched for published/unpublished RCTs of antipsychotic-induced sialorrhea (any definition) in adults, up to 06/12/2023. We assessed global/local inconsistencies, publication bias, risk of bias (RoB2), and confidence in the evidence, conducting subgroup/sensitivity analyses...
October 11, 2023: Molecular Psychiatry
https://read.qxmd.com/read/37816542/airway-clearance-strategies-and-secretion-management-in-amyotrophic-lateral-sclerosis
#26
REVIEW
Kristen L McHenry
Amyotrophic lateral sclerosis (ALS) is a rare, neurodegenerative motor neuron disease that affects voluntary muscle movement. Often, difficulty in coughing, breathing, and swallowing are sequela associated with the condition, and the presence of bulbar muscle predominant weakness results in deleterious effects on airway clearance and secretion management. This narrative review will provide practical guidance for clinicians treating this population. Cough insufficiency in this population typically manifests as a prolonged, slow, weak cough effort that impedes the clearability of secretions and airway protection...
January 24, 2024: Respiratory Care
https://read.qxmd.com/read/37779004/-basic-and-clinical-research-based-on-clinical-questions-reduction-of-antipsychotic-medication-induced-adverse-events
#27
JOURNAL ARTICLE
Shuhei Ishikawa
Antipsychotics are widely used to manage mental illnesses. They have, however, been reported to cause various adverse events. Two studies were conducted to resolve clinical questions related to adverse events caused by antipsychotic medications in clinical practice. The first adverse event studied was clozapine-induced sialorrhea (CIS), a common adverse event. There is no established standard treatment for CIS because the underlying mechanism remains unclear. Therefore, this study aimed to identify the cause of CIS...
2023: Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan
https://read.qxmd.com/read/37685630/salivary-complaints-in-burning-mouth-syndrome-a-cross-sectional-study-on-500-patients
#28
JOURNAL ARTICLE
Federica Canfora, Elena Calabria, Gianrico Spagnuolo, Noemi Coppola, Niccolò Giuseppe Armogida, Cristina Mazzaccara, Domenico Solari, Luca D'Aniello, Massimo Aria, Giuseppe Pecoraro, Michele Davide Mignogna, Stefania Leuci, Daniela Adamo
BACKGROUND: Xerostomia and sialorrhea often accompany Burning Mouth Syndrome (BMS) despite no change in saliva quantity. This study analyzed BMS patients with different symptom combinations: burning only (B), burning and xerostomia (BX), burning and sialorrhea (BS), and burning with xerostomia and sialorrhea (BXS), using a large sample of 500 patients from the University of Naples Federico II. METHODS: After a medical evaluation, patients were divided into four groups based on their reported symptoms: B (140), BX (253), BS (49), and BXS (58)...
August 26, 2023: Journal of Clinical Medicine
https://read.qxmd.com/read/37644923/a-challenging-case-of-wilson-s-disease
#29
Rita João Soares, Nuno Monteiro, João Machado, Joana Silva Marques, Ana Nunes
Wilson's disease (WD) is an inherited disorder characterized by the accumulation of copper in various organs, particularly the liver, central nervous system, and cornea. The clinical presentation of WD can vary widely. Diagnosis requires a combination of clinical and biochemical findings. We present a case of a 20-year-old woman who presented to the Emergency Room with progressive motor decline. She exhibited characteristic neurological symptoms and signs, such as hypomimia, bradyphrenia, bradykinesia, dysarthria, sialorrhea, upper limb dystonia, and wing-beating tremor...
July 2023: Curēus
https://read.qxmd.com/read/37633776/clozapine-and-neutrophil-response-in-patients-of-african-descent-a-six-month-multinational-prospective-open-label-clinical-trial
#30
JOURNAL ARTICLE
Deanna L Kelly, Matthew Glassman, Ikwunga Wonodi, Gopal Vyas, Charles M Richardson, Evaristus Nwulia, Heidi J Wehring, Taiwo Oduguwa, Marie Mackowick, Maria Mananita S Hipolito, Olawunmi Peters, Narayan Rai, Jaeboon Park, Adeola O Adebayo, David A Gorelick, Elaine Weiner, Fang Liu, Ann Marie Kearns, Heather A Adams, Raymond C Love, Shuo Chen, Ayodeji Olaniyan, Nicholas Ambulos, Darius McKoy, Madhulika C Nallani, Sophie Lanzkron, Mulu Mengistab, Brian Barr, Erica Davis, Rahman Lawal, Robert W Buchanan, Richard Adebayo
INTRODUCTION: Clozapine is the most effective antipsychotic for treatment-resistant schizophrenia, but it is markedly underutilized, particularly in the US Black population, partly because of concern over clozapine-associated low absolute neutrophil count (ANC). People of African descent have a lower normative ANC range than the White population, which is associated with a specific "ACKR1-null" ("Duffy null") CC genotype (SNP rs2814778) on the ACKR1 gene, termed benign ethnic neutropenia (BEN)...
August 24, 2023: Schizophrenia Research
https://read.qxmd.com/read/37629280/examining-the-role-of-sublingual-atropine-for-the-treatment-of-sialorrhea-in-patients-with-neurodevelopmental-disabilities-a-retrospective-review
#31
JOURNAL ARTICLE
Kayla Durkin Petkus, Garey Noritz, Laurie Glader
Sialorrhea is common in children with neurodevelopmental disabilities (NDD) and is reported in >40% of children with cerebral palsy (CP). It causes a range of complications, including significant respiratory morbidity. This single-center retrospective chart review aims to document sublingual atropine (SLA) utilization to guide further study in establishing its role in secretion management for children with NDD. A chart review was completed for patients with NDD ≤ 22 years of age treated with SLA at a free-standing children's hospital between 1 January 2016 and 1 June 2021...
August 11, 2023: Journal of Clinical Medicine
https://read.qxmd.com/read/37615978/otolaryngology-and-the-pregnant-patient
#32
JOURNAL ARTICLE
Claire M Lawlor, M Elise Graham, Lynsey C Owen, Lauren F Tracy
IMPORTANCE: Pregnancy may result in physiologic and pathologic changes in the head and neck. Otolaryngologists may need to intervene medically or surgically with pregnant patients. Careful consideration of risks to both the gravid patient and the developing fetus is vital. OBSERVATIONS: Patients may present with otolaryngologic complaints exacerbated by or simply occurring during their pregnancy. Symptoms of hearing loss, vertigo, rhinitis or rhinosinusitis, epistaxis, obstructive sleep apnea, sialorrhea, voice changes, reflux, subglottic stenosis, and benign and malignant tumors of the head and neck may prompt evaluation...
October 1, 2023: JAMA Otolaryngology—Head & Neck Surgery
https://read.qxmd.com/read/37597972/a-systematic-chart-review-of-pharmacological-interventions-in-patients-with-clozapine-induced-hypersalivation
#33
JOURNAL ARTICLE
Emre Mutlu, Elçin Özçelik Eroğlu, F Özlem Coşkun, Doğukan Koçyiğit, İrem K N Canpolat, Hanife Avcı, Aygün Ertuğrul, A Elif Anıl Yağcıoğlu
OBJECTIVES: To investigate the efficacy and tolerability of medications, such as mouthwash use of 1 % atropine sulfate and tropicamide drops, oral amitriptyline and amisulpride used for clozapine-induced hypersalivation (CIH). METHODS: The medical charts of inpatients with psychotic disorders between 2010 and 2022 were reviewed retrospectively. We detected 161 patients with eligible data who received or commenced clozapine. Primary outcome was defined as the percentage change in the diameter of a wet patch on the pillow (DWP) for improvements in CIH...
August 17, 2023: Schizophrenia Research
https://read.qxmd.com/read/37520231/pathophysiology-and-management-of-risperidone-induced-sialorrhea-case-report
#34
Tyler Torrico, Angad Kahlon
BACKGROUND: Among antipsychotics, sialorrhea is most associated with clozapine, and when it occurs, it is uncomfortable, socially stigmatizing, and can contribute to medication non-adherence. Risperidone has a generally negligible muscarinic activity compared to clozapine, and yet, multiple reports of severe sialorrhea associated with risperidone have been reported. CASE PRESENTATION: This case report describes risperidone-induced sialorrhea that was unintentionally masked by simultaneous clonidine administration that was intended to treat hypertension...
2023: Frontiers in Psychiatry
https://read.qxmd.com/read/37461166/botulinum-toxin-in-the-treatment-of-sialorrhea-in-severe-neurological-patients-with-tracheotomy
#35
JOURNAL ARTICLE
Mengmeng Shao, Keyang Chen, Xiaoyun Wu, Jingjing Lin, Mingxia Jiang, Feinan Zhuo, Zhaojian Ying, Yuanyuan Huang
OBJECTIVE: To observe the clinical effect of botulinum toxin type A (BTA) injection into the salivary glands of the severe neurological patients with tracheotomy METHODS: Seven patients with severe neurological disorders after tracheotomy and obvious drooling symptoms were enrolled. BTA was injected into bilateral parotid glands and submandibular glands under the guidance of ultrasound. Unstimulated salivary flow rate (uSFR) and Drooling Severity and Frequency Scale (DSFS) were used to evaluate drooling before injection, 1 week, and 4 weeks after injection...
July 17, 2023: Brain and Behavior
https://read.qxmd.com/read/37457841/botox-injection-in-treatment-of-sialorrhea-in-children-with-cerebral-palsy
#36
JOURNAL ARTICLE
Mohamadreza Ghazavi, Samira Rezaii, Mohadese Ghasemi, Neda Azin, Mohsen Reisi
BACKGROUND: The occurrence of sialorrhea (drooling) in children with cerebral palsy is one of the important complications of this disease, which is associated with the impaired quality of life of patients and also the dissatisfaction of their parents. Botox injection in the salivary glands is one of the treatment methods that has recently received special attention in these patients, but there are still many challenges regarding its effectiveness and safety. We aimed to test the effectiveness and safety of botulinum toxin type A in reducing sialorrhea in children with cerebral palsy...
2023: American Journal of Neurodegenerative Disease
https://read.qxmd.com/read/37433092/optimizing-pharmacologic-treatment-for-als-to-improve-outcomes-and-quality-of-life
#37
JOURNAL ARTICLE
Karen Lynch
Just 3 disease-modifying treatments-edaravone, riluzole, and sodium phenylbutyrate and taurursodiol (PB/TURSO)-are currently FDA approved to slow progression of amyotrophic lateral sclerosis (ALS). A fourth therapy has been recently approved under accelerated approval and is contingent upon verification of clinical benefit in confirmatory trials(s). Therapy selection is based largely upon patient characteristics, as guidelines have not been updated since the recent approval of PB/TURSO or accelerated approval of tofersen...
June 2023: American Journal of Managed Care
https://read.qxmd.com/read/37368654/pooled-safety-analysis-of-incobotulinumtoxina-in-the-treatment-of-neurological-disorders-in-adults
#38
JOURNAL ARTICLE
Wolfgang H Jost, Petr Kaňovský, Michael A Hast, Angelika Hanschmann, Michael Althaus, Atul T Patel
The pooled incidences of treatment-emergent adverse events (TEAEs) were examined by indication using the integrated clinical database of Merz-sponsored, placebo-controlled, or repeat-dose studies of incobotulinumtoxinA in adults with cervical dystonia, blepharospasm, limb spasticity, sialorrhea, or essential tremor of the upper limb. Overall incidences of TEAEs, serious TEAEs, TEAEs leading to discontinuation, fatal TEAEs, TEAEs of special interest (TEAESIs; indicating possible toxin spread), and treatment-related (TR) events were determined for incobotulinumtoxinA and placebo after a single injection and for repeated dose cycles of incobotulinumtoxinA...
May 23, 2023: Toxins
https://read.qxmd.com/read/37326935/is-there-a-treatment-effective-and-safe-for-sialorrhea-in-people-with-amyotrophic-lateral-sclerosis-als-summary-of-a-cochrane-systematic-review
#39
REVIEW
Teresa Anna Cantisani
No abstract text is available yet for this article.
June 16, 2023: Neurological Sciences
https://read.qxmd.com/read/37282351/self-reported-oral-moistening-disorders-in-obstructive-sleep-apnea-a-scoping-review
#40
REVIEW
Maryam Raoof, Merel C Verhoeff, Razieh Kooshki, Ghizlane Aarab, Frank Lobbezoo
BACKGROUND: obstructive sleep apnea (OSA) is a highly prevalent problem with significant consequences. Continuous positive airway pressure (CPAP) and oral mandibular advancement device (MAD) are considered the standard treatments for OSA. Patients may experience self-reported oral moistening disorders (OMD) (i.e., xerostomia or drooling) at the beginning, throughout, and after treatment. This affects oral health, quality of life, and treatment effectiveness. The exact nature of the associations between OSA and self-reported OMD is still unknown...
June 6, 2023: Journal of Oral Rehabilitation
keyword
keyword
6366
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.